You are here: Home » 2024 » December » Archives for 18th

EMGA secures US$90M from EIB for Brazil’s BTG Pactual  

LONDON, Dec. 18, 2024 (GLOBE NEWSWIRE) — Emerging Markets Global Advisory LLP (EMGA) announces today they have secured US$90M debt finance for their long–standing Brazil–based client, BTG Pactual.

The US$90 million senior unsecured loan was provided by EIB and the transaction follows on from a very recent transaction also advised by EMGA for USD$210m.

Sajeev Chakkalakal, Managing Director and Head of Investment Banking at EMGA, said: “This was a fantastic add–on transaction to the US$ 210m green financing facility that we raised for BTG from EIB. In this instance, this financing is aimed at funding BTG’s SME Lending portfolios and has an especially high development impact given that the finance will support small business development in disadvantaged regions of Brazil, and the additional focus on female entrepreneurs. EIB remains a key investor relationship for EMGA, and we are proud to have helped them increase their presence in Brazil as part of their broader EIB Global strategy.”

Jeremy Dobson, Managing Director, and Head of Operations at EMGA, added: “It was a pleasure to work with BTG again on this additional financing from EIB. We look forward to continuing our strong track record of arranging financing in Brazil and the rest of Latin America.”

BTG Pactual: BTG is the largest investment bank in Latin America, the 6th largest bank in Brazil by shareholders equity and a key player in providing loans and guarantees to a broad set of clients, from SMEs to large corporations. BTG is a pioneer in promoting climate finance in Brazil and plays a pivotal role in channeling resources towards projects with a positive impact in the community. 

EIB: EIB is the European Investment Bank (EIB), the European Union's investment bank and is the largest multilateral financial institution in the world. The EIB finances and invests both through equity and debt solutions and focuses on the areas of climate, environment, small and medium–sized enterprises (SMEs), development, cohesion and infrastructure. 

Emerging Markets Global Advisory LLP (EMGA), with offices in London and New York, helps financial institutions and corporates seeking new debt or equity capital. EMGA’s multi–national team collectively have decades of experience in closing over USD 9bn of debt and private equity transactions for their clients within the world’s emerging markets and frontier economies, including Brazil which remains a key market. With a proven track record in capital formation and strategic advisory throughout diverse economic cycles, EMGA continues to deliver geographic reach and a diverse service offering, solidifying its place in the market as a pre–eminent emerging markets specialized boutique investment bank.

Contact info@emergingmarketsglobaladvisory.com


GLOBENEWSWIRE (Distribution ID 1001029556)

Trident and the Democratic Republic of Congo, Office of the President through National Intelligence Sign Collaboration Agreement (PROTOCOLE D’ACCORD DE COLLABORATION) to Develop and Implement a National E-Government System

Trident to Explore Digital Transformation of Government Services in the Democratic Republic of the Congo
Trident’s Blockchain–Powered Digital Authentication Platform to Enhance Security and Efficiency of Government Service Delivery

SINGAPORE, Dec. 18, 2024 (GLOBE NEWSWIRE) — Trident Digital Tech Holdings Ltd (“Trident” or the “Company,” NASDAQ: TDTH), a leading catalyst for digital transformation in technology optimization services and Web 3.0 activation based in Singapore, today announced the signing of a landmark collaboration agreement with the Democratic Republic of Congo (the “DRC” or “Republic”), represented by the President of the Republic via the National Intelligence Agency, to drive digital transformation in the DRC for effective, accountable, and transparent governance.

Under this collaboration agreement, Trident will explore the development of a comprehensive electronic government (“e–GOV”) system for the DRC, aimed at digitizing the Congolese government’s administrative framework through the integration of cutting–edge technologies, including blockchain, to provide secure and efficient government services to citizens while protecting personal data.

The agreement establishes a framework for both parties to enter into a definitive agreement for Trident to develop and implement a platform that will manage the digital identities and data of Congolese citizens. This platform will provide secure and streamlined access to a wide range of government services, including business registration, land registries, immigration services, civil registry, as well as digital payment and approval functions for government services. Each service will be customized to meet the specific needs of the DRC.

Soon Huat Lim, Founder, Chairman, and CEO of Trident, stated, “We are honored to collaborate with the Democratic Republic of Congo on this transformative project that will revolutionize how citizens interact with government services through secure digital identities. Our platform enables robust authentication processes via encrypted digital identities, enhancing security while optimizing the citizen experience when interacting with government services. This collaboration with the DRC is a significant validation of our technological capabilities and our commitment to developing secure and efficient digital solutions tailored to various scenarios. This agreement marks a significant milestone in our company’s growth trajectory, demonstrating our ability to deliver large–scale digital transformation solutions to global standards. We are confident that the success of this initiative will open opportunities to implement similar digital identity and secure authentication solutions for other clients seeking to develop their digital infrastructure.”

Justin Inzun Kakiak, Director General of the DRC’s National Intelligence Agency, commented, “Our selection of Trident for this crucial digital transformation initiative reflects our commitment to adopting and coordinating innovative solutions for the benefit of our country and our citizens. This e–Government system will significantly improve access to government services in our country, and we are delighted to move forward with Trident on this groundbreaking initiative.”

About Trident

Trident is a leading catalyst for digital transformation in digital optimization, technology services, and Web 3.0 activation worldwide, based in Singapore. The Company offers commercial and technological digital solutions designed to optimize its clients’ experience with their end–users by promoting digital adoption and self–service.

Tridentity, the Company’s flagship product, is an innovative and highly secure blockchain–based identity solution designed to provide secure single sign–on authentication capabilities to integrated third–party systems across various industries. Tridentity aims to offer unparalleled security features, ensuring the protection of sensitive information and preventing potential threats, thus promising a new secure era in the global digital landscape in general, and in South Asia etc.

Beyond Tridentity, the company’s mission is to become the global leader in Web 3.0 activation, notably connecting businesses to a reliable and secure technological platform, with tailored and optimized customer experiences.

Safe Harbor Statement

This announcement contains statements that may constitute “forward–looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward–looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. The Company may also make written or oral forward–looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in announcements and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs, plans, and expectations, are forward–looking statements. Forward–looking statements involve inherent risks and uncertainties, including the possibility that a definitive agreement will not be concluded as contemplated under the collaboration agreement discussed in this announcement, and the possibility that the e–GOV system will not materialize as contemplated under the collaboration agreement or a definitive agreement if and once concluded. A number of factors could also cause actual results to differ materially from those contained in any forward–looking statement, including but not limited to the following: the Company’s strategies, future business development, and financial condition and results of operations; the expected growth of the digital solutions market; the political, economic, social and legal developments in the jurisdictions that the Company operates in or in which the Company intends to expand its business and operations; the Company’s ability to maintain and enhance its brand. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this announcement is as of the date of this announcement, and the Company does not undertake any obligation to update any forward–looking statement, except as required under applicable law.

Investor/Media Contacts

Investor Relations Robin Yang, Partner

ICR, LLC

Email: investor@tridentity.me

Phone: +1 (212) 321–0602

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/60d62bc2–fb8b–4540–bfb9–ef48e13b5fd0


GLOBENEWSWIRE (Distribution ID 9321249)

Mavenir and Spry Fox Networks (SFN) Announce Strategic Partnership to Accelerate API Monetization in the Telecom Industry

Communication Service Providers (CSPs) can now rapidly deploy a comprehensive GSMA Open Gateway based platform by leveraging a pre–integrated solution that combines Mavenir's Digital Enablement (MDE) Portfolio and Spry Fox Networks' QP Cloud MONET. This powerful combination provides CSPs with end–to–end API monetization capabilities, enabling them to quickly capitalize on new revenue streams.

RICHARDSON, Texas, Dec. 18, 2024 (GLOBE NEWSWIRE) — Mavenir, the cloud–native network infrastructure provider building the future of networks, and Spry Fox Networks (SFN), a pioneer in API monetization and network exposure, today announced a strategic partnership aimed at transforming the way Communication Service Providers (CSPs) can monetize their networks and offer innovative API–driven services to aggregators, hyperscalers, and application service providers.

Through this partnership, Mavenir’s robust, next–generation telecom offerings – including Core, and Mavenir Digital Enablement (MDE) 1 Business Support System (BSS), Product Catalog, Converged Charging solutions, Partner Management, and Digital Marketplace – will be integrated with SFN’s advanced API monetization platform, enabling CSPs to unlock new revenue streams by exposing and monetizing their network services. This joint solution allows CSPs to manage the entire lifecycle of network–based API services – from onboarding and exposure to monetization, analytics, and monitoring, while maintaining full control over access and usage.

Key Highlights of the Partnership:

  • GSMA–Certified Open GW: SFN’s QP Cloud MONET (QPCM) is the first Channel Partner Solution to become certified with Open Gateway API Certification, providing out–of–the–box implementation of several CAMARA and Custom APIs. QPCM is specifically designed to enable MNOs and MVNOs to monetize their networks in the quickest possible time. QPCM is built with security and privacy protection at its core and supports all the Authorisation flows defined in CAMARA.
  • Pre–Integrated API Monetization Stack: Mavenir’s Digital Enablement portfolio provides pre–integrated BSS, Charging, Mediation, Partner Management, Billing, and Settlement capabilities for monetization of APIs exposed via QPCM. This significantly reduces the time to launch and fully monetize new API products by providing an out–of–the–box workflow for lead–to–order and order–to–cash using pay–per–use, subscription, tiered, SLA–based charging models for customers and partners – including Developers, Consumers, Enterprises, and Aggregators.
  • Network Capability Exposure: Mavenir’s Combo NEF/SCEF (Network Exposure Function and Service Capability Exposure Function) provides exposure of standard defined network APIs to third–party applications via QPCM. NEF/SCEF, when combined with Mavenir’s full Core solutions (Packet Core, IMS, and Messaging), offers significant advantages and delivers faster time–to–market for a wide variety of Open GW APIs.
  • Fastest time–to–market for Open GW APIs: The combined and pre–integrated solution offers the fastest and most risk–free approach for CSPs to launch CAMARA/Open GW APIs. The out–of–the–box approach aims to offer an adjunct solution for CSPs that can open new revenue streams with API monetization without disrupting their existing Network and BSS/OSS/IT ecosystem.

“We’re excited to partner with Spry Fox Networks to offer our customers an integrated solution that simplifies the exposure and monetization of network services,” said Sandeep Singh, SVP, GM, Digital Business Enablement at Mavenir. “This collaboration will enable CSPs to unlock new revenue potential, drive business agility, and meet the growing demand for innovative, API–driven services in the telecommunications industry.”

Jignesh Sorathia, Head 5G, Spry Fox Networks, added, “Together with Mavenir and its industry–leading MDE portfolio, we’re providing a powerful platform for CSPs to open up their networks in a controlled, secure, and profitable way. Our combined expertise will help CSPs move towards a more flexible, API–first model, supporting a wide range of verticals, including 5G, IoT, and beyond.”

The partnership aims to accelerate digital transformation for CSPs, enabling them to evolve in a rapidly changing telecommunications landscape and seize opportunities in the growing API economy.

About Spry Fox Networks (SFN):
Spry Fox Networks (SFN) excels in delivering comprehensive wireless network solutions, with a particular emphasis on Network APIs that leverage the GSMA Open Gateway framework to empower Mobile Network Operators (MNOs) and Mobile Virtual Network Operators (MVNOs) to effectively monetize their networks.

SFN's innovative and agile Telco API solution solves challenges across multiple business verticals such as fintech, ad–tech, media & broadcasting and automotive.

About Mavenir:
Mavenir is building the future of networks today with cloud–native, AI–enabled solutions which are green by design, empowering operators to realize the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award–winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com

Mavenir PR Contact:
Emmanuela Spiteri
PR@mavenir.com

______________________________
1 MDE is also the monetization engine behind Mavenir's inhouse OpenGW solution for Mavenir customers who use larger Mavenir ecosystem solutions.


GLOBENEWSWIRE (Distribution ID 9321070)

A Bitget se prepara para a conformidade MiCA com um futuro centro regional europeu

VICTORIA, Seychelles, Dec. 18, 2024 (GLOBE NEWSWIRE) — A Bitget, líder em bolsa de criptomoedas do mundo e empresa Web3, está explorando o estabelecimento de seu centro regional europeu na Lituânia como parte de sua expansão estratégica na União Europeia. A mudança está alinhada com a estrutura Markets in Crypto–Assets (MiCA) da UE, que fornece um ambiente regulatório unificado para os criptoativos em toda a região.

A empresa está se preparando ativamente para a conformidade de acordo com a estrutura MiCA, incluindo planos de estabelecer um escritório e recrutar equipes de conformidade e operações na Lituânia.

“Apreciamos verdadeiramente as autoridades regulatórias da UE por sua liderança e visão de nutrir um ambiente seguro e vibrante para a inovação digital. Nossa visão para a Europa vai além da expansão de negócios. O continente está na vanguarda da revolução cripto, e temos o compromisso de contribuir com seu ecossistema crescente de startups de cripto”, disse Hon Ng, diretor jurídico da Bitget. “Ao estabelecer um centro na União Europeia, estamos demonstrando nosso forte compromisso de manter os mais altos padrões de segurança e conformidade”, ele adicionou.

A Bitget trabalha de maneira consistente em direção a cumprir a conformidade regulatória em todo o mundo em jurisdições favoráveis a criptomoedas, mantendo licenças em grandes mercados como Polônia, Austrália e Itália. A bolsa recentemente entrou de novo no mercado do Reino Unido, oferecendo serviços de cripto totalmente em conformidade e está buscando aprovações regulatórias em mais de 15 jurisdições em todo o mundo. Isso inclui a Lituânia, onde a Bitget assegura seu registro de cripto, o que mostra sua dedicação em operar de maneira segura e transparente na Europa.

A empresa também planeja colaborar estreitamente com os reguladores europeus para garantir que seus produtos atendam a todos os requisitos regulatórios, ao mesmo tempo que prioriza a proteção dos ativos e dados dos usuários. À medida que a estrutura MiCA entra em vigor, os passos proativos da Bitget a impulsionam para que se torne a bolsa em conformidade de crescimento mais rápido.

Sobre a Bitget

Fundada em 2018, a Bitget é líder em bolsa de criptomoedas e empresa Web3 do mundo. Atendendo a mais de 45 milhões de usuários em mais de 150 países e regiões, a bolsa Bitget está comprometida em ajudar os usuários a operar de forma mais inteligente com seu recurso pioneiro de copy trading e outras soluções de operação, oferecendo acesso em tempo real ao preço do Bitcoin, preço do Ethereum e outros preços de criptomoedas. Anteriormente conhecida como BitKeep, a Bitget Wallet é uma carteira de criptografia multicadeia de classe mundial que oferece uma variedade de soluções e recursos Web3 integrais, incluindo funcionalidade de carteira, swap de tokens, NFT Marketplace, navegador DApp e muito mais.

A Bitget está na vanguarda da adoção de criptomoedas por meio de parcerias estratégicas, como seu papel de Parceiro Oficial de Criptomoedas da Principal Liga de Futebol do mundo, LALIGA, nos mercados do Leste, Sudeste Asiático e América Latina, bem como um parceiro global dos atletas nacionais turcos Buse Tosun Çavuşoğlu (campeão mundial de luta livre), Samet Gümüş (medalhista de ouro de boxe) e İlkin Aydın (equipe nacional de vôlei), para inspirar a comunidade global a abraçar o futuro da criptomoeda.

Para mais informações, visite: Site | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet
Para consultas de mídia, entre em contato com: media@bitget.com

Aviso de risco: Os preços dos ativos digitais podem flutuar e sofrer volatilidade de preços. Invista somente o que pode perder. É possível que o valor de seu investimento seja afetado e não atinja suas metas financeiras ou não consiga recuperar seu investimento principal. Procure sempre uma consultoria financeira independente e considere sua própria experiência e situação financeira. O desempenho no passado não é uma medida confiável do desempenho no futuro. A Bitget não se responsabiliza por quaisquer perdas incorridas por você. Nada do que consta neste documento deve ser interpretado como orientação financeira.

Uma foto que acompanha este anúncio está disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/007638ef–6c42–486f–b50e–afbc2fbd3ec1


GLOBENEWSWIRE (Distribution ID 1001029386)

Bitget bereitet sich mit bevorstehendem europäischen Regionalzentrum auf MiCA-Konformität vor

VICTORIA, Seychellen, Dec. 18, 2024 (GLOBE NEWSWIRE) — Bitget, das weltweit führende Unternehmen für Kryptowährungsaustausch und Web3, prüft im Rahmen seiner strategischen Expansion in der Europäischen Union die Einrichtung seines Regionalzentrums für Europa in Litauen. Dieser Schritt steht im Einklang mit dem EU–Rahmenwerk für Märkte für Krypto–Assets (Markets in Crypto–Assets, MiCA), der darauf abzielt, ein einheitliches regulatorisches Umfeld für Krypto–Assets in der gesamten Region zu schaffen.

Das Unternehmen bereitet sich aktiv auf die Einhaltung der MiCA–Rahmenbedingungen vor, einschließlich der Pläne, ein Büro einzurichten und Personal für Compliance und Betrieb in Litauen einzustellen.

„Wir schätzen die Regulierungsbehörden der EU sehr für ihre Führungsrolle und ihre Vision, ein sicheres und lebendiges Umfeld für digitale Innovationen zu schaffen. Unsere Vision für Europa geht über die Geschäftsexpansion hinaus. Der Kontinent steht an der Spitze der Krypto–Revolution, und wir sind entschlossen, zu seinem wachsenden Ökosystem von Krypto–Startups beizutragen“, so Hon Ng, Chief Legal Officer von Bitget. „Durch die Einrichtung eines Zentrums in der Europäischen Union zeigen wir unser starkes Engagement für die Einhaltung höchster Sicherheits– und Compliance–Standards“, fügte er hinzu.

Bitget arbeitet konsequent daran, die Einhaltung gesetzlicher Vorschriften weltweit in kryptofreundlichen Gerichtsbarkeiten zu gewährleisten und verfügt über Lizenzen in wichtigen Märkten wie Polen, Australien und Italien. Die Börse ist kürzlich wieder in den britischen Markt eingetreten und bietet vollständig konforme Krypto–Dienstleistungen an. Sie bemüht sich um behördliche Genehmigungen in mehr als 15 Ländern weltweit. Dazu gehört auch Litauen, wo Bitget seine Krypto–Registrierung sichert und damit sein Engagement für einen sicheren und transparenten Betrieb in Europa unter Beweis stellt.

Das Unternehmen plant außerdem eine enge Zusammenarbeit mit europäischen Regulierungsbehörden, um sicherzustellen, dass seine Produkte alle regulatorischen Anforderungen erfüllen, wobei der Schutz der Vermögenswerte und Daten der Benutzer im Vordergrund steht. Mit Inkrafttreten des MiCA–Rahmenwerks wird Bitget durch seine proaktiven Schritte zur am schnellsten wachsenden konformen Börse.

Über Bitget

Bitget wurde 2018 gegründet und ist die weltweit führende Kryptowährungsbörse und Web3–Firma. Mit über 45 Millionen Benutzern in mehr als 150 Ländern und Regionen hat sich die Bitget–Börse dazu verpflichtet, den Benutzern mit ihrer bahnbrechenden Copy–Trading–Funktion und anderen Handelslösungen zu helfen, intelligenter zu handeln. Sie bietet gleichzeitig Echtzeit–Zugang zum Bitcoin–Kurs, Ethereum–Kurs und anderen Kryptowährungspreisen. Die ehemals unter dem Namen BitKeep bekannte Bitget Wallet ist eine erstklassige Multichain–Krypto–Wallet, die eine Reihe umfassender Web3–Lösungen und –Funktionen, darunter Wallet–Funktionen, Token Swap, NFT Marketplace, DApp–Browser und mehr, bietet.

Bitget steht an vorderster Front, wenn es darum geht, die Akzeptanz von Kryptowährungen durch strategische Partnerschaften voranzutreiben, wie z. B. als offizieller Krypto–Partner der weltbesten Fußball–Liga LALIGA für den OST–, SEA– und LATAM–Markt, sowie als globaler Partner der türkischen Nationalsportler Buse Tosun Çavuşoğlu (Weltmeister im Ringen), Samet Gümüş (Goldmedaillengewinner im Boxen) und İlkin Aydın (Volleyball–Nationalmannschaft), um die globale Gemeinschaft zu inspirieren, Teil der Zukunft der Kryptowährung zu werden.

Weitere Informationen finden Sie unter: Website | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet
Für Medienanfragen wenden Sie sich bitte an: media@bitget.com

Risikowarnung: Die Preise für digitale Vermögenswerte können schwanken und Kursschwankungen unterliegen. Investieren Sie nur das, was zu verlieren Sie sich leisten können. Der Wert Ihrer Anlage kann beeinträchtigt werden, und es ist möglich, dass Sie Ihre finanziellen Ziele nicht erreichen oder Ihren Kapitaleinsatz nicht zurückerhalten können. Sie sollten immer eine unabhängige Finanzberatung in Anspruch nehmen und Ihre eigene finanzielle Erfahrung und finanzielle Leistungsfähigkeit berücksichtigen. Die Ergebnisse der Vergangenheit sind kein verlässlicher Maßstab für künftige Ergebnisse. Bitget haftet nicht für etwaige Verluste, die Sie erleiden. Die hierin enthaltenen Informationen sind nicht als Finanzberatung auszulegen.

Ein Foto zu dieser Mitteilung ist verfügbar unter https://www.globenewswire.com/NewsRoom/AttachmentNg/007638ef–6c42–486f–b50e–afbc2fbd3ec1


GLOBENEWSWIRE (Distribution ID 1001029386)

Bitget se prépare à l’entrée en application du cadre MiCA avec la création d’un futur hub régional européen

VICTORIA, Seychelles, 18 déc. 2024 (GLOBE NEWSWIRE) — Bitget, la première bourse de crypto–monnaies et société Web3 au monde, envisage la création en Lituanie de son hub régional européen dans le cadre de son expansion stratégique dans l’Union européenne. Cette démarche fait suite aux exigences du cadre de réglementation des marchés des crypto–actifs (MiCA) mis en place par l’UE afin de fournir un environnement réglementaire unifié pour les crypto–actifs dans l’ensemble de la région.

L’entreprise se prépare activement au respect des exigences du cadre MiCA en matière de conformité, notamment en prévoyant de créer un bureau en Lituanie et d’y recruter du personnel de conformité et d’exploitation.

« Nous apprécions sincèrement le leadership et la vision dont les autorités réglementaires de l’UE font preuve en matière de création d’un environnement sûr et dynamique pour l’innovation numérique. Notre vision de l’Europe va au–delà de la seule expansion commerciale. Le continent est à l’avant–garde de la révolution cryptographique et nous nous engageons à contribuer au développement de son écosystème croissant de startups cryptographiques », a déclaré Hon Ng, directeur juridique de Bitget. « En établissant un hub au sein de l’Union européenne, nous démontrons avec fermeté notre engagement à satisfaire aux normes de sécurité et de conformité les plus élevées », a–t–il ajouté.

Bitget s’efforce constamment de se conformer aux réglementations en vigueur dans le monde entier, dans toutes les juridictions favorables à la cryptographie, et détient des licences d’exploitation sur des marchés majeurs tels que la Pologne, l’Australie et l’Italie. La bourse de crypto–monnaies a récemment fait son retour sur le marché britannique où elle offre des services de cryptographie pleinement conformes, et sollicite les approbations réglementaires requises dans plus de 15 juridictions à travers le monde. Cela inclut la Lituanie, où Bitget a obtenu son homologation cryptographique, indiquant ainsi sa volonté d’exercer ses activités de manière sécurisée et transparente en Europe.

La société prévoit également de collaborer étroitement avec les régulateurs européens afin de garantir que ses produits répondent à toutes les exigences réglementaires tout en accordant la priorité à la protection des actifs et des données des utilisateurs. Alors que le cadre MiCA entre en application, les mesures proactives prises par Bitget en font la bourse de crypto–monnaies respectueuse de la réglementation qui connaît actuellement la croissance la plus rapide.

À propos de Bitget

Fondée en 2018, Bitget est la première bourse de crypto–monnaies et société Web3 au monde. Au service de plus de 45 millions d’utilisateurs répartis dans plus de 150 pays et régions, la bourse Bitget s’engage à aider les utilisateurs à trader plus intelligemment grâce à sa fonctionnalité révolutionnaire de copy trading et ses autres solutions de trading, tout en fournissant un accès en temps réel aux cours du Bitcoin, de l’Ethereum et d’autres cryptomonnaies. Anciennement connu sous le nom de BitKeep, Bitget Wallet est un portefeuille cryptographique multi–chaînes de classe mondiale qui offre une gamme de solutions et de fonctionnalités Web3 complètes, dont notamment des fonctionnalités de portefeuille, d’échange de jetons, une place de marché NFT et un navigateur DApp, entre autres.

Bitget est le fer de lance de l’adoption des cryptomonnaies grâce à des partenariats stratégiques, comme en témoigne son rôle de partenaire crypto officiel de la meilleure ligue de football au monde, LALIGA, sur les marchés de l’EST, de l’ASEAN et de l’Amérique latine, ou encore son rôle de partenaire mondial des athlètes olympiques turcs Buse Tosun Çavuşoğlu (championne du monde de lutte), Samet Gümüş (médaillé d’or de boxe) et İlkin Aydın (équipe nationale de volley–ball). Bitget a pour vocation d’inciter la population mondiale à embrasser l’avenir des cryptomonnaies.

Pour obtenir de plus amples informations, consultez : Site Internet | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet
Pour toute demande média, veuillez nous contacter à l’adresse suivante : media@bitget.com

Mise en garde sur les risques : Les cours des actifs numériques peuvent fluctuer et connaître une certaine volatilité. Investissez uniquement la somme que vous pouvez vous permettre de perdre. La valeur de votre investissement peut être affectée et il est possible que vous n’atteigniez pas vos objectifs financiers ou que vous ne parveniez pas à récupérer votre investissement principal. Nous vous encourageons à toujours solliciter les conseils d’un spécialiste financier indépendant et à tenir compte de votre expérience et de votre situation financière. Les performances passées ne constituent pas un indicateur fiable des résultats futurs. Bitget ne sera en aucun cas responsable des pertes que vous pourriez subir. Nulle disposition des présentes ne saurait être interprétée comme un conseil d’ordre financier.

Une photo accompagnant cette annonce est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/007638ef–6c42–486f–b50e–afbc2fbd3ec1


GLOBENEWSWIRE (Distribution ID 1001029386)

Brains Bioceutical Expande Oferta de Canabinóides Líder do Setor com D9-THC e CBN, Abrindo Novas Fronteiras para o Desenvolvimento de Medicamentos

VANCOUVER, British Columbia, Dec. 18, 2024 (GLOBE NEWSWIRE) — A Brains Bioceutical Corp. (Brains Bio), líder global em Ingredientes Farmacêuticos Ativos (APIs) de canabinóides naturais e compatíveis com GMP, anuncia a expansão da sua oferta líder do setor. O Canabinol (CBN) está disponível como um API certificado pela EU–GMP, o D9–tetra–hidrocanabinol (THC) está em uma forma cristalina sólida, passando por um trabalho aprimorado de otimização da estabilidade e a validação final está sendo realizada com o Canabigerol (CBG).

Essas novas adições complementam o portfólio atual da Brains Bio, com o CBD API sendo usado em mais de 30 estudos clínicos e pré–clínicos, incluindo um Estudo de Fase III de Epilepsia Refratária concluído – enviado à Marketing Authorisation – e um Estudo de Fase II de Transtorno de Uso de Opioides. Com distribuição global imediata de amostras, a Brains Bio abre novos caminhos para pesquisa clínica, desenvolvimento de produtos e inovação terapêutica.

A Próxima Onda das Terapias à Base de Canabinóides
O portfólio expandido da Brains Bio é um exemplo da dedicação da empresa com o desenvolvimento de canabinóides para pesquisa e desenvolvimento farmacêutico. As ofertas incluem produtos formulados e APIs compatíveis com os requisitos de monografia da Ph. Eur. e da ICH Q7, criados para apoiar programas clínicos aprovados por regulamentações visando necessidades médicas críticas não atendidas. Essas APIs, com aplicações potenciais em uma ampla gama de usos terapêuticos, incluindo distúrbios neurológicos, dor crônica e condições inflamatórias, estão prontas para impulsionar avanços clínicos inovadores.

Ampliação das Histórias de Sucesso Existentes
A indústria farmacêutica já testemunhou a integração bem–sucedida de medicamentos à base de canabinóides. Vários medicamentos aprovados pela FDA e pela EMA têm demonstrado benefícios clínicos significativos, incluindo:

  • Epidiolex (CBD): Uma solução oral para o tratamento de crises epilépticas associadas às síndromes de Lennox–Gastaut e Dravet (aprovado pela FDA/ EMA).
  • Marinol & Syndros (Dronabinol): Formulações para náuseas e vômitos induzidos por quimioterapia e anorexia relacionada à AIDS (aprovado pela FDA/EMA).
  • Sativex (CBD/THC): Um tratamento para espasticidade na EM e outras condições neurológicas (aprovado pela EMA).

Esses sucessos destacam o potencial terapêutico das terapias à base de canabinóides e sua crescente aceitação pela comunidade médica, com a Brains Bio permanecendo dedicada ao avanço da compreensão científica dos canabinóides.

“Um marco para a indústria farmacêutica”
“A introdução de CBN API, D9 THC e CBG de alta qualidade é um marco para a Brains Bio e para toda a indústria farmacêutica”, disse Ricky Brar, CEO e presidente da Brains Bioceutical Corp. “Esses produtos capacitam pesquisadores e desenvolvedores de medicamentos a ultrapassar os limites da ciência de canabinóides, acelerando a entrega de terapias transformadoras para pacientes em todo o mundo. Essa conquista é mais um exemplo do nosso compromisso inabalável de fornecer APIs que atendam aos mais altos padrões de segurança, qualidade e consistência.”

Um Mercado Pronto para Crescer
O Relatório Global de Pesquisa de Mercado Farmacêutico Derivado de Canabinóides 2024 projeta um aumento significativo, de US $ 884,3 milhões em 2021 para US $ 4,87 bilhões até 2034 (CAGR de 13,4%). Este aumento indica o aumento do reconhecimento da eficácia das terapias com canabinóides na abordagem de uma ampla gama de condições médicas.

O portfólio de APIs da Brains Bio representa a próxima fronteira, fornecendo aos inovadores farmacêuticos um ingrediente robusto e em conformidade para acelerar o desenvolvimento de tratamentos à base de canabinóides aprovados pela regulamentação.

Solicitação de Amostras e Consultas
As APIs THC e CBN da Brains Bioceutical Corp. já estão disponíveis para distribuição de amostras. Para mais informações, as empresas farmacêuticas e organizações de pesquisa podem contatar a empresa em ir@brainsbio.com.

Sobre a Brains Bioceutical Corp.
A Brains Bioceutical Corp. é líder global no desenvolvimento e fabricação de APIs de canabinóides naturais para a indústria farmacêutica. Seu foco no avanço da pesquisa com canabinóides se traduz em soluções inovadoras que atendem às necessidades médicas críticas não atendidas, transformando o futuro da medicina.

INFO@BRAINSBIO.COM
BRAINSBIO.COM
1–855–927–2476

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/b460b7ca–9a31–4a41–a012–23d26e61ef5d


GLOBENEWSWIRE (Distribution ID 9321095)

Brains Bioceutical weitet das branchenführende Cannabinoid-Angebot auf D9-THC und CBN aus, um neue Grenzen in der Wirkstoffentwicklung zu erschließen

VANCOUVER, British Columbia, Dec. 18, 2024 (GLOBE NEWSWIRE) — Brains Bioceutical Corp. (Brains Bio), ein weltweit führendes Unternehmen für natürliche GMP–konforme cannabinoide Pharmawirkstoffe (API), gibt die Erweiterung seines branchenführenden Angebots bekannt. Cannabinol (CBN) ist als EU–GMP–zertifizierter API erhältlich. D9–Tetrahydrocannabinol (THC) hat eine feste kristalline Form, wird auf eine erhöhte Stabilität hin optimiert und einer abschließenden Validierung als Cannabigerol (CBG) unterzogen.

Diese neuen Ergänzungen komplettieren das aktuelle Sortiment von Brains Bio, da der CBD API derzeit in über 30 klinischen und vorklinischen Studien verwendet wird, darunter eine abgeschlossene Phase–III–Studie zu refraktärer Epilepsie (eingereicht für die Marktzulassung) und eine Phase–II–Studie zum Missbrauch opioider Wirkstoffe. Durch die sofortige globale Bereitstellung von Produktproben eröffnet Brains Bio neue Wege für die klinische Forschung, Produktentwicklung und therapeutische Innovation.

Die nächste Generation von Cannabinoid–basierten Therapien
Das erweiterte Sortiment von Brains Bio trägt dem Engagement des Unternehmens für die Cannabinoid–Entwicklung im Bereich von Arzneimittelforschung und –entwicklung Rechnung. Das Angebot umfasst formulierte Produkte und API konform zu den Anforderungen von Ph. Eur. Monograph und ICH Q7, und ist darauf ausgelegt, regulatorisch zulassungsfähige klinische Programme für wichtige ungedeckte medizinische Bedarfe zu unterstützen. Diese API mit potenziellen Anwendungsmöglichkeiten für ein breites therapeutisches Spektrum einschließlich neurologischer Erkrankungen, chronischer Schmerzen und entzündlicher Erkrankungen sollen wegweisende klinische Fortschritte auf den Weg bringen.

Bestehende Erfolgsgeschichten als Ausgangsbasis
Die Arzneimittelindustrie kann bereits auf die erfolgreiche Integration von Cannabinoid–basierten Medikamenten zurückblicken. Mehrere durch die FDA und EMA zugelassenen Medikamente zeigen einen erheblichen klinischen Nutzen, darunter:

  • Epidiolex (CBD): Eine Lösung zum Einnehmen für die Behandlung epileptischer Anfälle im Zusammenhang mit dem Lennox–Gastaut–Syndrom und Dravet–Syndrom (zugelassen durch die FDA/EMA).
  • Marinol & Syndros (Dronabinol): Formulierungen gegen Übelkeit und Erbrechen, die durch eine Chemotherapie ausgelöst wurden, sowie bei Anorexie in Verbindung mit AIDS (zugelassen durch die FDA/EMA).
  • Sativex (CBD/THC): Eine Behandlung für spastische Anfälle bei MS und anderen neurologischen Erkrankungen (zugelassen durch die EMA).

Diese Erfolge untermauern das therapeutische Potenzial von Cannabinoid–basierten Therapien und ihre wachsende Akzeptanz in der medizinischen Community, und Brains Bio engagiert sich auch weiterhin dafür, das wissenschaftliche Verständnis von Cannabinoiden voranzubringen.

„Ein Meilenstein für die Arzneimittelindustrie“
„Die Einführung von qualitativ hochwertigem CBN API, D9 THC und CBG ist ein wegweisender Augenblick für Brains Bio und für die gesamte Arzneimittelindustrie“, so Ricky Brar, CEO und Chairperson von Brains Bioceutical Corp. „Diese Produkte ermöglichen es der Forschung und Wirkstoffentwicklung die Grenzen der Cannabinoid–Wissenschaft zu erweitern und die Bereitstellung revolutionärer Therapien für Patientinnen und Patienten auf der ganzen Welt zu beschleunigen. Dieser Erfolg spiegelt unser unerschütterliches Engagement für die Herstellung von API wider, die den höchsten Standards in puncto Sicherheit, Qualität und Konsistenz entsprechen.“

Ein auf Wachstum ausgelegter Markt
Der Global Cannabinoid Derived Pharmaceutical Market Research Report 2024 (Marktforschungsbericht 2024 für weltweite Cannabinoid–abgeleitete Arzneimittel) prognostiziert einen erheblichen Anstieg von 884,3 Millionen USD im Jahr 2021 auf 4,87 Milliarden USD bis zum Jahr 2034 (CAGR von 13,4 %). Dieser steile Anstieg spiegelt das erhöhte Bewusstsein für die Wirksamkeit cannabinoider Therapien in der Bekämpfung zahlreicher medizinischer Erkrankungen wider.

Das API–Sortiment von Brains Bio markiert den nächsten Meilenstein, da Innovatoren in der Arzneimittelindustrie einen zuverlässigen und konformen Wirkstoff für die Weiterentwicklung regulatorisch zugelassener Cannabinoid–basierter Behandlungen erhalten.

Anforderung von Produktproben und Anfragen
Die THC– und CBN–API von Brains Bioceutical Corp. sind jetzt als Produktprobe erhältlich. Arzneimittefirmen und Forschungsorganisationen erreichen das Unternehmen bezüglich Anfragen oder weiterer Informationen über ir@brainsbio.com.

Über Brains Bioceutical Corp.
Brains Bioceutical Corp. ist ein weltweit führendes Unternehmen in der Entwicklung und Herstellung natürlicher cannabinoider API für die Arzneimittelindustrie. Im Fokus der Cannabinoid–Forschung steht die Übertragung auf innovative Lösungen für wichtige medizinische Anforderungen, um eine neue Zukunft der Medizin einzuläuten.

INFO@BRAINSBIO.COM
BRAINSBIO.COM
1–855–927–2476

Ein Foto zu dieser Mitteilung ist verfügbar unter https://www.globenewswire.com/NewsRoom/AttachmentNg/b460b7ca–9a31–4a41–a012–23d26e61ef5d


GLOBENEWSWIRE (Distribution ID 9321095)

Brains Bioceutical élargit son offre de cannabinoïdes leaders sur le marché avec le D9-THC et le CBN, et ouvre ainsi de nouvelles possibilités en matière de développement de médicaments

VANCOUVER, Colombie–Britannique, 18 déc. 2024 (GLOBE NEWSWIRE) — Brains Bioceutical Corp. (Brains Bio), leader mondial dans la fabrication d’ingrédients pharmaceutiques actifs (IPA) à base de cannabinoïdes naturels et conformes aux BPF, annonce élargir sa gamme de produits leaders sur le marché. Le cannabinol (CBN) est disponible en tant qu’IPA certifié BPF au sein de l’UE. Le D9–tétrahydrocannabinol (THC) est une structure cristalline solide, et des travaux visant à optimiser la stabilité du cannabigérol (CBG) et à effectuer les dernières étapes en vue de sa validation sont en cours.

Ces nouveaux ajouts viennent compléter le portefeuille actuel de Brains Bio. Le CBD est un IPA utilisé dans le cadre de plus de 30 études cliniques et précliniques, y compris une étude de phase III portant sur l’épilepsie réfractaire ayant débouché sur une demande de mise sur le marché, et une étude de phase II portant sur les troubles liés à l’usage d’opiacés. Par le biais d’une distribution immédiate d’échantillons à l’échelle mondiale, Brains Bio ouvre de nouvelles voies pour la recherche clinique, le développement de produits et l’innovation thérapeutique.

La nouvelle vague de traitements à base de cannabinoïdes dévoilée
Le portefeuille élargi de Brains Bio reflète la détermination de la société à développer des cannabinoïdes pour la recherche et le développement pharmaceutique. Parmi sa gamme de produits, on peut citer des produits formulés et des IPA conformes à la Pharmacopée européenne (Ph. Eur.) et aux exigences de l’ICH Q7, conçues pour soutenir les programmes cliniques approuvés par les organismes de réglementation et ciblant des besoins médicaux fondamentaux non satisfaits. Ces IPA, avec des applications potentielles pour une large gamme d’usages thérapeutiques, notamment concernant les troubles neurologiques, les douleurs chroniques et les maladies inflammatoires, sont en passe d’entraîner des progrès cliniques révolutionnaires.

S’appuyer sur les réussites antérieures
L’industrie pharmaceutique a déjà assisté à l’intégration réussie de médicaments à base de cannabinoïdes. Plusieurs médicaments autorisés par la FDA et l’EMA démontrent des bénéfices cliniques significatifs, notamment :

  • Epidiolex (CBD) : solution buvable destinée à traiter les crises d’épilepsie associées aux syndromes de Lennox–Gastaut et de Dravet (autorisé par la FDA/l’EMA).
  • Marinol et Syndros (Dronabinol) : formulations pour les nausées et vomissements induits par la chimiothérapie et l’anorexie liée au SIDA (autorisés par la FDA/l’EMA).
  • Sativex (CBD/THC) : traitement contre la spasticité liée à la SEP et à d’autres maladies neurologiques (autorisé par l’EMA).

Ces réussites mettent en évidence le potentiel thérapeutique des traitements à base de cannabinoïdes et leur acceptation croissante au sein de la communauté médicale. Brains Bio continue à se consacrer à faire progresser les connaissances scientifiques sur les cannabinoïdes.

« Une étape clé pour l’industrie pharmaceutique »
« L’introduction de CBN, un IPA de haute qualité, du D9 THC et du CBG constitue un moment historique pour Brains Bio et pour l’industrie pharmaceutique dans son ensemble, » a déclaré Ricky Brar, PDG et président de Brains Bioceutical Corp. « Ces produits permettent aux chercheurs et aux développeurs de médicaments de repousser les limites de la science autour des cannabinoïdes, et de fournir ainsi plus rapidement des traitements révolutionnaires pour les patients du monde entier. Cette prouesse reflète notre engagement inébranlable à fournir des IPA qui répondent aux normes les plus strictes en matière de sécurité, de qualité et de régularité. »

Un marché appelé à se développer
Le Global Cannabinoid Derived Pharmaceutical Market Research Report (Rapport d’étude de marché mondial sur les produits pharmaceutiques dérivés des cannabinoïdes) de 2024 prévoit une augmentation significative du marché, qui devrait passer de 884,3 millions de dollars en 2021 à 4,87 milliards de dollars d’ici 2034 (TCAC de 13,4 %). Cette augmentation reflète la reconnaissance croissante de l’efficacité des thérapies à base de cannabinoïdes dans le traitement de très nombreuses maladies.

Le portefeuille d’IPA de Brains Bio représente l’avenir, et offre aux pionniers de l’industrie pharmaceutique un ingrédient solide et conforme pour accélérer le développement de traitements à base de cannabinoïdes autorisés en vertu des réglementations.

Demandes d’échantillons et de renseignements
Des échantillons des IPA de Brains Bioceutical Corp., le THC et le CBN, peuvent être distribués dès à présent. Pour toute demande de renseignements et d’informations complémentaires, les laboratoires pharmaceutiques et les organismes de recherche peuvent contacter la société à l’adresse ir@brainsbio.com.

À propos de Brains Bioceutical Corp.
Brains Bioceutical Corp. est un leader mondial dans le développement et la fabrication d’IPA à base de cannabinoïdes naturels pour l’industrie pharmaceutique. La société s’emploie à faire avancer les recherches sur les cannabinoïdes, ce qui se traduit par des solutions innovantes qui répondent à des besoins médicaux fondamentaux non satisfaits, dans l’optique de révolutionner l’avenir de la médecine.

INFO@BRAINSBIO.COM
BRAINSBIO.COM
1–855–927–2476

Une photo accompagnant cette communication est disponible à l’adresse https://www.globenewswire.com/NewsRoom/AttachmentNg/b460b7ca–9a31–4a41–a012–23d26e61ef5d


GLOBENEWSWIRE (Distribution ID 9321095)

Israel Continues to Attack Gaza Amid Ceasefire Negotiations

The General Assembly adopts a resolution on a “Demand for ceasefire in Gaza” during the resumed 10th Emergency Special Session of the General Assembly on “Illegal Israeli actions in occupied East Jerusalem and the rest of the Occupied Palestinian Territory”. Credit: UN Photo/Manuel Elías

By Oritro Karim
UNITED NATIONS, Dec 18 2024 – After 14 months of conflict between Israel and Palestine, talks of a ceasefire agreement have headed in a promising direction. The proposed agreement entails the release of hostages in Gaza, the withdrawal of Israeli troops from Palestinian land, and a strategy for displaced Gazans to safely return to their homes in the northern region of the enclave. Despite both Israeli and Palestinian officials expressing optimism over this agreement, hostilities from the Israeli Defense Forces (IDF) continue to endanger the lives and infrastructures of thousands of Gazans.

On December 16, Israeli Defense Minister Israel Katz informed the Knesset Foreign Affairs and Defense Committee that Israel is “closer than ever” to securing a deal with Hamas to free the Israeli hostages and end hostilities in Palestine. A senior Palestinian official echoed this sentiment to reporters, describing the negotiations between the two parties as in a “decisive and final phase”.

“We believe – and the Israelis have said this – that we’re getting closer, and no doubt about it, we believe that, but we also are cautious in our optimism,” said White House spokesperson John Kirby. Despite talks of a ceasefire swirling in the media and among top officials, the IDF continues to conduct airstrikes on densely populated areas and have issued new orders of evacuation, exacerbating the already dire humanitarian crisis in Gaza.

“In Gaza city, humanitarian partners say hostilities escalated over the weekend – particularly in areas affected by the new evacuation orders – leaving more Palestinians killed and injured,” said United Nations (UN) spokesperson Stephane Dujarric.

On December 12, two airstrikes hit three residential buildings in an Al Nuseirat camp in central Gaza. According to figures from the Office of the United Nations High Commissioner for Human Rights (OHCHR), these airstrikes killed an estimated 49 Palestinians, including at least 17 children. Three days later, the IDF issued a direct airstrike on a school in East Tuffah, causing considerable damage to the building and injuring several civilians.

Local authorities have confirmed that approximately 110 Palestinians were killed from December 14-15 in the Gaza Strip. On December 16, the IDF conducted a bombardment on a school-turned-shelter in Khan Younis, located in the southern region of the enclave. According to the United Nations Relief and Works Agency for Palestinian Refugees (UNRWA), at least 13 people died and 48 were injured in this attack.

UNRWA Senior Emergency Officer Louise Wateridge described the brutality of this attack to UN News, saying, “I have been to Nasser Hospital this morning. One of the children I spoke to, her name was Mona, 17 years old; she had very severe injuries to her leg – she had very severe shrapnel wounds – and she was in the hospital with her sister…their mother was crushed to death under the rubble.”

The IDF claimed that the shelter was used as a training compound that would coordinate attacks against Israel. Hamas refuted these claims and accused the IDF of trying to “justify indiscriminate killings”.

Manal Tafesh, a resident of the Khan Younis camp who has lost her brother and children in the attack, informed reporters that people were eating dinner in their homes when the airstrikes hit the camp. “Our children are gone, our children are gone. Our youth is gone. Our children are gone, and our lineage ended. When will this darkness end?” Tafesh said.

On December 16, the UN confirmed that more than 45,000 civilians have been killed over the past 14 months of conflict in Gaza. Catherine Russell, the Executive-Director of the United Nations Children’s Fund (UNICEF), stated in a press release that approximately 14,500 Gazan children have been killed.

According to Dujarric, Israeli authorities had issued two new evacuation orders on December 13 and 14. These orders went into effect in Gaza City, northern Gaza, and the Deir al Balah area. The UN’s partners described 250 families moving southward from northern Gaza and roughly 450 families fleeing their homes in Deir al Balah. According to UN estimates, approximately 1,500 Gazans were displaced overnight on December 14 from Izbet Beit Hanoun.

Living conditions continue to grow worse in displacement shelters as the harsh winter season approaches. According to Russell, famine looms in the north and humanitarian access remains severely restricted.

On December 13, the World Food Programme (WFP) posted a statement on X (formerly known as Twitter), highlighting the urgency of the growing levels of famine among displaced persons in Gaza. WFP’s Head of Emergency Communications, Jonathan Dumont, warned that due to the restriction of humanitarian aid deliveries, most Gazans were likely not getting enough to eat. “To prevent famine we need to find a way to get a consistent flow of food in,” Dumont said.

Dumont went on to describe the deteriorating living conditions in Gaza, saying, “There’s no electricity or running water or sewage (treatment). Almost everyone has lost their home. A lot of people are living in tents.”

Russell added that infectious diseases have run rampant in displacement shelters, with an estimated 800 documented cases of hepatitis and 300 cases of chickenpox. Additionally, thousands of children are suffering from skin rashes and acute respiratory infections, which have been exacerbated by the cold weather.

IPS UN Bureau Report

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);